- Home
- NMAI vs SIGA Comparison
NMAI vs SIGA Comparison
Compare NMAI & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | SIGA |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.5M | 401.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | NMAI | SIGA |
|---|---|---|
| Price | $13.43 | $4.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 109.2K | ★ 839.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 13.14% | 12.77% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.64 | 0.32 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $224.81 |
| P/E Ratio | $21.39 | ★ $14.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.31 | $4.29 |
| 52 Week High | $13.96 | $9.62 |
Technical Indicators
Market Signals| Indicator | NMAI | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 38.14 |
| Support Level | $12.57 | N/A |
| Resistance Level | $13.90 | $6.98 |
| Average True Range (ATR) | 0.27 | 0.19 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 80.17 | 29.77 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.